Diagnosed, Then What? Alzheimer's Blood Tests Are Outrunning Treatment and Care Capacity

A weak signal in life sciences: FDA-cleared blood-based Alzheimer's diagnosis is moving into primary care faster than UK and US health systems can confirm, treat, or support the patients identified, opening a diagnosis-to-care capacity and financing gap.

The consensus on Alzheimer's diagnostics is that scalable blood tests are an unambiguous good: pull diagnosis out of specialist gatekeeping, route patients to disease-modifying drugs sooner, and the field tips toward early intervention. The 2026 evidence inverts that comfort. The first FDA-cleared primary-care blood test is now in use across more than two thousand US sites, yet the drugs it points to are restricted in the US and still rejected by NICE; UK memory services concede they could not absorb disease-modifying treatments at current capacity; and the workforce is shrinking against a record cost base. The non-obvious signal is a widening diagnosis-to-care gap, with the inflection inside twelve months.

Signal Identification

This is a capability disruption in the diagnostic layer running ahead of the treatment, workforce, and reimbursement layers that determine whether a diagnosis converts to care. A diagnostics story has become a care-capacity and financing story.

What's Changing

The diagnostic layer has crossed a commercial threshold. Labcorp has rolled out Roche's Elecsys pTau-181 across more than 2,200 US patient service centres as the first FDA-cleared blood test for initial Alzheimer's assessment in primary care, with a 97.9% negative predictive value, designed to rule out Alzheimer's and reduce referrals against a national neurologist shortage (SelectScience, 05/05/2026). Demand is large: 7.4 million Americans aged 65+ live with clinical Alzheimer's, annual care costs reach a record $409 billion in 2026 (up $25 billion year on year), and only 14% of adults report ever discussing brain health with a doctor (Alzheimer's Association, 21/04/2026).

Treatment and care layers have not moved with it. A peer-reviewed UK study of old age psychiatrists finds only about 6% of memory services fully comply with NICE guidance on biomarker and additional diagnostic tests, and only around 36% believe their services could deliver disease-modifying treatments within a year (Age and Ageing, 01/05/2026). A BMC Geriatrics national survey of English memory services confirms variability in diagnosis, workforce-driven service constraints, and geographic disparities in access (Bioengineer, 20/02/2026).

The funding layer runs opposite. NICE opened a third consultation on donanemab and lecanemab on 31 March 2026 after three refusals; the drugs delay progression by about 4-6 months but require infusions, MRI monitoring and intensive surveillance, with a committee meeting set for 10 June 2026 (The Pharmaceutical Journal, 01/04/2026). Alzheimer's Society warns "globally more people are starting to access these drugs, but the UK is falling behind", with over 30 Alzheimer's drugs in late-stage trials adding to the queue (Alzheimer's Society, 20/03/2026).

Disruption Pathway

The pathway runs in three stages. Stage one is diagnostic conversion: primary-care blood tests identify a wave of mild-cognitive-impairment and early-Alzheimer's patients previously screened out by specialist gatekeeping, with the Labcorp rollout setting the US template. Stage two is referral overload: those patients enter UK memory services largely unable to confirm or treat at speed, and US neurology pathways already short on specialists. Stage three is the funding decision point: a NICE reversal in June 2026 multiplies demand against the same service base, while a fourth refusal locks UK patients into a diagnosis-without-treatment pathway as the 30-plus late-stage pipeline queues behind.

Stress concentrates at three points. UK memory-service capacity is the binding constraint, with 6% NICE compliance and 36% one-year readiness signalling a structural mismatch between diagnostic supply and confirmation capability. US workforce supply is the binding constraint there: the Alzheimer's Association flags growing shortages across the dementia-care workforce against a $409 billion care bill. Reimbursement and care-pathway design is the system-level constraint: a diagnosis routed to drugs the NHS will not fund, or into a Medicare-Medicaid system without aligned monitoring and post-diagnostic support, converts the test into a patient-experience liability. Adaptations sit at two levels: operational (memory-service redesign, biomarker pathways, primary-care training) and financial (outcomes-based contracts, post-diagnostic support budgets).

Why This Matters

For NHS commissioners, CMS and state Medicaid payers, diagnostic developers, biopharma sponsors and long-term care operators, the assumption to revise is that scalable diagnosis is the bottleneck. On the available evidence, the binding constraint has shifted to confirmation capacity, treatment access, and dementia-care workforce supply. Systems that scale diagnostics without parallel investment in memory-service capacity, biomarker pathways, and post-diagnostic support will manufacture a cohort of diagnosed patients with nowhere to go. Boards should expect commissioning conditionality tying diagnostic uptake to demonstrated care capacity; payers should expect demand-side pressure conventional cost-effectiveness was not built to absorb.

Decision-action posture for this signal: Prepare, the diagnostic capability is live and the capacity gap measurable, but the commissioning response window is open through 2026-2027, so most actors should build memory-service capacity, workforce and outcomes-based payment architecture now and commit on the NICE June 2026 decision.

Implications

Taken together, the sources point to a durable reset of where the binding constraint sits in the Alzheimer's care pathway, not a transient adoption lag. The inflection window is 2026-2027, set by the NICE June 2026 decision, the rate of US primary-care uptake, and whether memory-service and workforce investment moves before the diagnosed cohort accumulates. Diagnostic firms and biopharma sponsors that pair products with capacity, training, and outcomes-based payment design will land; those treating scale-up as commercial-only hit a politically visible bottleneck. Payers that ration through inaction inherit the access-equity problem.

Early Indicators to Monitor

• NICE's 10 June 2026 committee draft reverses earlier refusals on donanemab or lecanemab, or attaches conditions tied to memory-service capacity.
• NHS England or DHSC announces memory-service capacity funding or a dementia plan refresh naming disease-modifying treatments.
• A second FDA-cleared primary-care Alzheimer's blood test enters the US market, or Labcorp publishes early uptake or referral-reduction data.
• CMS or a major state Medicaid programme ties blood-test reimbursement to defined post-diagnostic-support commitments.
• A peer-reviewed UK study reports memory-service one-year readiness for disease-modifying therapies rising from the 36% baseline.

Disconfirming Signals

• NICE issues a fourth refusal on donanemab and lecanemab in 2026, capping demand-side pressure on memory services.
• UK memory-service NICE compliance rises materially above the 6% baseline in published audits.
• US primary-care uptake of the Elecsys pTau-181 test stalls below deployment targets.
• A workforce announcement, statutory funding, or training pipeline materially expands the US dementia-care and neurology base.
• CMS Medicare Alzheimer's pathway data show diagnosis-to-treatment conversion holding up without access gaps.

Strategic Questions

• Should diagnostic firms tie scale-up to demonstrated memory-service capacity, or push volume and accept access-gap risk?
• At what NICE outcome do UK commissioners move from preparing for disease-modifying treatments to funding capacity build?
• Should biopharma sponsors offer outcomes-based contracts now, or wait for the June 2026 committee result?
• Which payer first ties blood-test reimbursement to post-diagnostic support, and what does that do to peer payers?

Keywords

Alzheimer's disease; blood-based diagnosis; pTau-181; primary care diagnostics; NICE; donanemab; lecanemab; memory services; disease-modifying therapies; dementia care workforce; outcomes-based contracting; post-diagnostic support

Bibliography

Source tiers: Tier 1, governments, regulators and intergovernmental bodies. Tier 2, think-tanks, academic institutes, major consultancies and quality data providers. Tier 3, quality journalism and specialist trade press. Tier 4, vendor, company and practitioner sources, used only as directional corroboration.

• Tier 1 Factors influencing implementation of an Alzheimer's blood test among UK old age psychiatrists. Age and Ageing (01/05/2026).
• Tier 2 2026 Alzheimer's Disease Facts and Figures. Alzheimer's Association (21/04/2026).
• Tier 2 Comment on NICE reviewing lecanemab and donanemab. Alzheimer's Society (20/03/2026).
• Tier 3 Labcorp launches FDA-cleared blood test to support Alzheimer's assessment in primary care. SelectScience (05/05/2026).
• Tier 3 NICE opens consultation on previously-rejected donanemab and lecanemab. The Pharmaceutical Journal (01/04/2026).
• Tier 3 Nationwide survey reveals dementia care in English memory clinics. Bioengineer (reporting BMC Geriatrics: Kelsey et al.) (20/02/2026).